Merck & Co.’s Big Ambition To ‘Democratize’ PCSK9s

 
• By Jessica Merrill
go big
Merck & Co. is planning a big Phase III program for its oral PCSK9 inhibitor • Source: Shutterstock

More from Cardiovascular

More from Therapeutic Category